iNtRON Biotechnology Balance Sheet Health
Financial Health criteria checks 6/6
iNtRON Biotechnology has a total shareholder equity of ₩89.4B and total debt of ₩0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are ₩91.0B and ₩1.6B respectively.
Key information
0%
Debt to equity ratio
₩0
Debt
| Interest coverage ratio | n/a |
| Cash | ₩54.38b |
| Equity | ₩89.37b |
| Total liabilities | ₩1.60b |
| Total assets | ₩90.97b |
Recent financial health updates
iNtRON Biotechnology (KOSDAQ:048530) Is In A Strong Position To Grow Its Business
Nov 15
We Think iNtRON Biotechnology (KOSDAQ:048530) Can Stay On Top Of Its Debt
May 03iNtRON Biotechnology (KOSDAQ:048530) Has A Rock Solid Balance Sheet
Jan 05Recent updates
iNtRON Biotechnology (KOSDAQ:048530) Is In A Strong Position To Grow Its Business
Nov 15We Think iNtRON Biotechnology (KOSDAQ:048530) Can Stay On Top Of Its Debt
May 03We Believe iNtRON Biotechnology's (KOSDAQ:048530) Earnings Are A Poor Guide For Its Profitability
Mar 24Does iNtRON Biotechnology's (KOSDAQ:048530) Share Price Gain of 81% Match Its Business Performance?
Feb 28iNtRON Biotechnology, Inc.'s (KOSDAQ:048530) Stock Is Going Strong: Is the Market Following Fundamentals?
Jan 31
iNtRON Biotechnology (KOSDAQ:048530) Has A Rock Solid Balance Sheet
Jan 05What iNtRON Biotechnology, Inc.'s (KOSDAQ:048530) 26% Share Price Gain Is Not Telling You
Dec 10iNtRON Biotechnology (KOSDAQ:048530) Share Prices Have Dropped 49% In The Last Five Years
Nov 26Financial Position Analysis
Short Term Liabilities: A048530's short term assets (₩57.1B) exceed its short term liabilities (₩1.1B).
Long Term Liabilities: A048530's short term assets (₩57.1B) exceed its long term liabilities (₩479.3M).
Debt to Equity History and Analysis
Debt Level: A048530 is debt free.
Reducing Debt: A048530 has no debt compared to 5 years ago when its debt to equity ratio was 26.9%.
Debt Coverage: A048530 has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: A048530 has no debt, therefore coverage of interest payments is not a concern.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/11 23:05 |
| End of Day Share Price | 2025/01/10 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
iNtRON Biotechnology, Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Sangsoo Kim | Goldman Sachs |